Amgen’s Phase III TRINOVA-1 trial of recurrent ovarian cancer drug yields positive results
The global, multicenter, double-blind study involved administering trebananib plus paclitaxel or placebo plus paclitaxel to more than 900 women suffering from recurrent partially platinum-sensitive or resistant epithelial ovarian,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.